Jamie Ahn Ku

Jamie Ahn Ku

Auto-generated profile, based on publicly available information

Jamie Ahn Ku

Department of Otolaryngology, Head and Neck Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SWShannon Wu
Shannon Wu
BCBonnie Chen
Bonnie Chen
CFChristopher W. Fleming
Christopher W. Fleming
ASAkeesha A. Shah
Akeesha A. Shah
CGChristopher C. Griffith
Christopher C. Griffith
JKJamie A. Ku
Jamie A. Ku

30 June 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
ABArslan Babar
Arslan Babar
NWNeil M. Woody
Neil M. Woody
AGAhmed I Ghanem
Ahmed I Ghanem
JTJillian Tsai
Jillian Tsai
NDNeal E. Dunlap
Neal E. Dunlap
JGJessica Geiger
Jessica Geiger
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (<200 mg/m2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.


18 August 2023 in Endocrine Practice
Verified
Journal Article
Closed access
SWShannon Wu
Shannon Wu
EMEric Lamarre MD
Eric Lamarre MD
JSJoseph Scharpf
Joseph Scharpf
BPBrandon Prendes
Brandon Prendes
JKJamie A. Ku
Jamie A. Ku
JGJessica Geiger
Jessica Geiger

26 December 2022 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
SLSara W. Liu
Sara W. Liu
AHAndrea L. Hanick
Andrea L. Hanick
JMJoseph B. Meleca
Joseph B. Meleca
MRMichael Roskies
Michael Roskies
SHStephen P. Hadford
Stephen P. Hadford
JKJamie A. Ku
Jamie A. Ku

8 July 2022 in Head & Neck
Verified
Journal Article
Open access
MLMaxwell Y. Lee
Maxwell Y. Lee
JLJonathan Lee
Jonathan Lee
SSSarah Stock
Sarah Stock
MBMario Belfiglio
Mario Belfiglio
BMBrian Matia
Brian Matia
JKJamie A. Ku
Jamie A. Ku
Background We sought to determine whether detection of cartilage invasion (CI) by computed tomography predicts oncologic outcomes after primary total laryngectomy. Methods Retrospective cohort study comparing oncologic outcomes between radiologic versus pathologic diagnosis. Results Assessment of clear CI versus gestalt CI resulted in 84% versus 48% specificity, 90.9% versus 80.3% positive predictive value (PPV), 60.6% versus 80.3% sensitivity, 44.7% versus 48% negative predictive value (NPV), respectively. Disease-free survival (DFS) was similar between cT4a and cT3/cT2 patients (p = 0.87). DFS trended towards superiority among pT3/pT2 versus pT4a patients (p = 0.18). DFS was similar among patients with CI on radiologist gestalt versus no CI (p = 0.94). Histologically confirmed CI was associated with a hazard ratio (HR) of 1.46 (p = 0.27), gestalt CI 1.13 (p = 0.70), and clear CI 1.61 (p = 0.10) for DFS. Conclusion Gestalt determination of CI results in high sensitivity but low specificity, while clear determination of CI results in moderate sensitivity and high specificity.